Skip to main content

Advertisement

Table 5 The forecast frequency of vascular endpoints and cost-effectiveness using insulin glargine or exenatide per 1,000 patients over 40 years under the three discontinuation scenarios.

From: Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled Type 2 diabetes in the United Kingdom

  No discontinuation Failures excluded Failures switched
  Exenatide Glargine Δ Exenatide Glargine Δ Exenatide Glargine Δ
Macrovascular
Ischaemic Heart Disease 122.2 121.2 -1.06 111.1 121.4 10.32 121.8 121.4 -0.36
Myocardial Infarction 387.4 388.2 0.82 351.9 387.7 35.79 386.1 387.7 1.61
Congestive heart Failure 84.9 92.6 7.68 77.7 92.3 14.59 85.4 92.3 6.87
Stroke 98.9 99.7 0.74 90.1 98.3 8.19 99.2 98.3 -0.89
Microvascular
Retinopathy 55.5 55.4 -0.03 50.7 55.4 4.73 55.3 55.4 0.11
Nephropathy 14.1 13.8 -0.29 12.7 14.1 1.41 14.1 14.1 -0.01
Neuropathy 12.9 12.9 0.04 11.8 12.9 1.13 13.1 12.9 -0.14
Hypoglycaemia events
Nocturnal 12901.2 34259.8 21358.6 11754.3 34269.6 22515.3 14804.9 34269.6 19464.7
Symptomatic 94479.7 55672.2 -38807.5 86080.9 55688.1 -30392.8 91090.4 55688.1 -35402.3
Severe 6622.0 6597.5 -24.5 6036.2 6598.1 561.9 6626.2 6598.1 -28.2
Fatal
Macrovascular 453.5 458.2 4.68 412.8 457.3 44.53 453.3 457.282 4.008
Microvascular 12.7 12.7 -0.02 11.6 12.8 1.18 12.9 12.752 -0.154
Other 532.8 528.1 -4.68 486.0 529.0 42.99 532.8 529.0 -3.845
Cost effectiveness
Discounted costs £14,567,526 £9,280,312   £13,255,912 £9,296,371   £14,092,624 £9,296,371  
Discounted QALYS 7,683 7,864   7,000 7,865   7,703 7,865  
ICER (£/QALY) Dominant (-£29,149) Dominant (-£4,579) Dominant (-£29,657)
  1. Note: the model takes an average of a series of runs in order for the resultant values to become stable. In taking this average non-integer values can be generated.